Charles Russell has advised on the first ever joint IPO on the Alternative Investment Market (AIM) and the Toronto Stock Exchange.

The firm acted for Canaccord Capital (Europe), which acted as the broker in the placing and flotation of Canadian drug company YM BioSciences.